- Home
- ADXN vs BIAF Comparison
ADXN vs BIAF Comparison
Compare ADXN & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- BIAF
- Stock Information
- Founded
- ADXN 2002
- BIAF 2014
- Country
- ADXN Switzerland
- BIAF United States
- Employees
- ADXN N/A
- BIAF 57
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ADXN Health Care
- BIAF Health Care
- Exchange
- ADXN Nasdaq
- BIAF Nasdaq
- Market Cap
- ADXN 8.0M
- BIAF 7.1M
- IPO Year
- ADXN N/A
- BIAF 2022
- Fundamental
- Price
- ADXN $8.73
- BIAF $0.25
- Analyst Decision
- ADXN Strong Buy
- BIAF Hold
- Analyst Count
- ADXN 1
- BIAF 1
- Target Price
- ADXN $30.00
- BIAF N/A
- AVG Volume (30 Days)
- ADXN 1.0K
- BIAF 531.9K
- Earning Date
- ADXN 09-01-2025
- BIAF 08-14-2025
- Dividend Yield
- ADXN N/A
- BIAF N/A
- EPS Growth
- ADXN N/A
- BIAF N/A
- EPS
- ADXN 0.10
- BIAF N/A
- Revenue
- ADXN $278,508.00
- BIAF $7,681,059.00
- Revenue This Year
- ADXN $86.57
- BIAF N/A
- Revenue Next Year
- ADXN N/A
- BIAF $20.00
- P/E Ratio
- ADXN $0.72
- BIAF N/A
- Revenue Growth
- ADXN N/A
- BIAF 4.99
- 52 Week Low
- ADXN $6.51
- BIAF $0.16
- 52 Week High
- ADXN $13.27
- BIAF $2.26
- Technical
- Relative Strength Index (RSI)
- ADXN 58.21
- BIAF 41.58
- Support Level
- ADXN $7.51
- BIAF $0.24
- Resistance Level
- ADXN $8.21
- BIAF $0.28
- Average True Range (ATR)
- ADXN 0.17
- BIAF 0.02
- MACD
- ADXN 0.11
- BIAF -0.00
- Stochastic Oscillator
- ADXN 100.00
- BIAF 29.50
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.